• Network Medicine Identifies Apigenin for Alzheimer’s

  2026-08-12

  A 2025 study used network proximity analysis to screen flavonoids against Alzheimer’s disease targets and identified Apigenin as the leading candidate among four experimentally tested compounds. Cellular validation linked its neuroprotective activity to mitochondrial preservation, reduced apoptosis, AKT/NF-κB pathway suppression, and regulation of microglial inflammatory states.

• GPC3-HSP70 mRNA Nanovaccine in HCC

  2026-08-11

  The reference study develops an mRNA nanovaccine that combines tandem GPC3 CTL epitopes with HSP70 and tumor-targeting peptide assembly to stimulate antitumor T-cell immunity in hepatocellular carcinoma. Its combination with anti-PD-L1 therapy produced stronger immune and antitumor effects than either strategy alone, while also illustrating the design and quality-control considerations relevant to therapeutic mRNA production.

• Methoxy-X04 for Amyloid Beta Imaging

  2026-08-11

  Methoxy-X04 turns amyloid pathology into a measurable fluorescent readout for plaque, oligomer, and vascular studies in Alzheimer’s disease models. This practical guide connects probe handling with rTMS mechanism studies, quantitative imaging, and troubleshooting for more reproducible amyloid beta fibril detection.

• Streptavidin-Cy3 for NPC Metastasis Assays

  2026-08-10

  Streptavidin-Cy3 converts biotinylated antibodies and nucleic-acid probes into a bright, modular readout for immunohistochemistry, in situ hybridization, immunofluorescence, and flow cytometry. This article translates a nasopharyngeal carcinoma metastasis study into practical assay designs, controls, and troubleshooting strategies.

• Whole-Blood Stimulation and Immunometabolism

  2026-08-09

  Zhao and colleagues present a standardized fresh whole-blood stimulation protocol that combines innate immune challenges with targeted metabolic intervention and cytokine measurement. The workflow preserves blood-derived cellular context while enabling systematic analysis of how metabolic pathways selectively shape immune outputs, providing a practical foundation for cohort studies and hypothesis generation.

• PAD4-IN-2 TFA: Translating NET Biology

  2026-08-08

  A translational perspective on how tumor-directed PAD4 inhibition, m-PBA-mediated uptake, and NET pathway control may improve mechanistic cancer research while guiding rigorous preclinical study design.

• IBDV VP3 Disrupts IRF7 Antiviral Signaling

  2026-08-07

  Wang et al. identify an immune-evasion mechanism in which infectious bursal disease virus VP3 suppresses IRF7-dependent type I interferon signaling and promotes proteasome-associated IRF7 loss. The study combines viral strain comparison, IRF7 gain- and loss-of-function experiments, inhibitor testing, and VP3 interaction analyses to connect host-factor degradation with enhanced viral replication.

• Kir4.1-ROS-p38 MAPK Pathway Drives Orofacial Neuropathic Pai

  2026-08-07

  This study uncovers how downregulation of Kir4.1 in trigeminal ganglion satellite glial cells leads to orofacial neuropathic pain through a cascade involving increased ROS, activation of p38 MAPK, and upregulation of pannexin 3. The mechanistic insights clarify pain sensitization pathways and suggest new molecular targets for intervention.

• PTGER4 Controls HDAC Activity and SPINK4 mRNA in Rectal Epit

  2026-08-06

  Anbazhagan et al. uncover a signaling cascade in rectal epithelial cells where PTGER4 activation by prostaglandin E2 modulates class IIa HDAC phosphorylation and upregulates SPINK4 mRNA. These findings elucidate a mechanistic link between mesenchymal stromal cell signaling and epithelial gene regulation, with implications for mucosal repair and inflammatory bowel disease.

• BCECF-AM: Advanced Workflows for Intracellular pH Measuremen

  2026-08-06

  BCECF-AM stands as a gold-standard, cell-permeable fluorescent probe for high-precision intracellular pH measurement across plant and mammalian systems. This article translates the latest experimental protocols and troubleshooting insights into actionable workflows, highlighting APExBIO's BCECF-AM for robust, reproducible live-cell assays.

• 3X (DYKDDDDK) Peptide: Powering Next-Gen Affinity Purificati

  2026-08-05

  The 3X (DYKDDDDK) Peptide unlocks robust, high-sensitivity workflows for recombinant protein purification and detection, outperforming standard epitope tags. By optimizing affinity and compatibility across advanced assays, it enables structural, functional, and translational discoveries with precision.

• Vorinostat and the New Apoptosis Paradigm in Cancer Research

  2026-08-05

  Explore how Vorinostat (SAHA, MK0683) empowers translational oncology by bridging HDAC inhibition, epigenetic modulation, and novel cell death pathways. This thought-leadership article dissects the latest mechanistic insights—including RNA Pol II degradation-dependent apoptosis—and delivers protocol-ready guidance, strategic recommendations, and a forward-looking vision for epigenetic drug development. The piece elevates beyond standard product pages by integrating primary literature, workflow assets, and APExBIO's reproducibility advantage.

• Praeruptorin A: Mechanistic Leverage in Ferroptosis and Infl

  2026-08-04

  Explore Praeruptorin A, a potent angular pyranocoumarin compound, as a multi-targeted ferroptosis inhibitor and advanced anti-inflammatory agent. This article delivers a mechanistic deep dive and strategic insight for translational research beyond standard protocols.

• Targeting MEK-ERK for Translational Research: Trametinib Ins

  2026-08-04

  Explore how Trametinib (GSK1120212) enables precise dissection of the MEK-ERK pathway in cancer and pain research, with deep mechanistic context and actionable protocols for translational scientists.

• Syringin: A Natural Product Strategy to Overcome RCC Drug Re

  2026-08-03

  This in-depth article offers translational researchers a mechanistic and strategic guide to leveraging Syringin—a rigorously characterized natural product—in renal cell carcinoma (RCC) research. It synthesizes the latest evidence on EGFR/PI3K/Akt pathway modulation, practical workflow recommendations, and the competitive landscape, while highlighting APExBIO’s high-purity Syringin as a benchmark for reproducible results.

8522 records 3/569 page Previous Next 12345 下5页 Last page